NFKB1 and breast carcinoma: In addition, our in vitro assays demonstrated that the silencing of PTEN in HER2-amplified breast cancer cells was indeed able to activate the PI3K pathway and an inflammatory signaling cascade driven by the STAT3/NF-κB pathway.